###begin article-title 0
###xml 72 78 <span type="species:ncbi:13443">coffee</span>
The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 278 283 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 343 349 <span type="species:ncbi:13443">coffee</span>
The response of serum cholesterol to diet may be affected by the apolipoprotein E (APOE) epsilon2/epsilon3/epsilon4 polymorphism, which also is a significant predictor of variation in the risk of coronary heart disease (CHD) and CHD death. Here, we test the hypothesis that the APOE polymorphism may modulate the cholesterol-raising effect of coffee.
###end p 3
###begin title 4
Objective
###end title 4
###begin p 5
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 30 36 <span type="species:ncbi:13443">coffee</span>
###xml 84 90 <span type="species:ncbi:13443">coffee</span>
We determined the effect of a coffee abstention period and a daily intake of 600 mL coffee on serum cholesterol and triglycerides with respect to the APOE polymorphism.
###end p 5
###begin title 6
Design
###end title 6
###begin p 7
###xml 25 28 <span type="species:ncbi:9606">men</span>
###xml 39 44 <span type="species:ncbi:9606">women</span>
###xml 133 139 <span type="species:ncbi:13443">coffee</span>
###xml 184 190 <span type="species:ncbi:13443">coffee</span>
121 healthy, non-smoking men (22%) and women (78%) aged 29-65 years, took part in a study with four intervention periods: 1 and 3) a coffee free period of three weeks, 2 and 4) 600 mL coffee/day for four weeks.
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
###xml 0 12 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;</italic>
###xml 239 244 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 196 202 <span type="species:ncbi:13443">coffee</span>
APOE epsilon2 positive individuals had significantly lower total cholesterol concentration at baseline (4.68 mmol/L and 5.28 mmol/L, respectively, p = 0.01), but the cholesterol-raising effect of coffee was not influenced significantly by APOE allele carrier status.
###end p 9
###begin title 10
Conclusions
###end title 10
###begin p 11
###xml 4 17 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949; </italic>
###xml 97 102 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 176 182 <span type="species:ncbi:13443">coffee</span>
The APOE epsilon 2 allele is associated with lower serum cholesterol concentration. However, the APOE polymorphism does not seem to influence the cholesterol-raising effect of coffee.
###end p 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 247 266 247 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;2, &#949;3 </italic>
###xml 270 278 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;4</italic>
###xml 444 463 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;2, &#949;3 </italic>
###xml 467 476 365 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;4 </italic>
###xml 626 627 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 740 741 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 742 743 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 788 802 680 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;2 </italic>
###xml 891 905 777 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;3 </italic>
###xml 942 956 822 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;4 </italic>
###xml 1033 1034 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1035 1036 909 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1037 1038 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1055 1060 929 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1231 1232 1075 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1233 1234 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1266 1271 1110 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1387 1388 1231 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1389 1390 1233 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1391 1392 1235 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1393 1395 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1474 1476 1318 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1504 1506 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1557 1559 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1623 1628 1467 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1635 1637 1473 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4 </italic>
###xml 1649 1654 1487 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1661 1663 1493 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4 </italic>
###xml 1735 1737 1567 1569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1738 1740 1570 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Apolipoprotein E (apoE) is a structural component of triglyceride-rich lipoproteins, chylomicrons, very-low-density lipoproteins (VLDL), and high-density-lipoproteins (HDL) [1]. Variation in the APOE gene sequence results in the 3 common alleles (epsilon2, epsilon3 and epsilon4), which can produce 6 different genotypes (epsilon2/epsilon2, epsilon2/epsilon3, epsilon2/epsilon4, epsilon3/epsilon3, epsilon3/epsilon4 and epsilon4/epsilon4). The epsilon2, epsilon3 and epsilon4 alleles encode three distinct forms of apoE (E2, E3 and E4) and have approximate frequencies of 8%, 77%, and 15%, respectively, in white populations [2]. ApoE3 seems to be the normal isoform in all known functions, while apoE4 and apoE2 can each be dysfunctional [3,4]. In most populations, individuals with the APOE epsilon2 allele display lower levels of plasma cholesterol compared with individuals carrying the APOE epsilon3 allele, whereas individuals with the APOE epsilon4 allele show higher levels of plasma cholesterol, especially LDL-cholesterol [1,2,5]. Subjects with APOE epsilon3/epsilon4 and epsilon4/epsilon4 genotypes absorb cholesterol effectively and have higher non-fasting serum triglyceride values than epsilon4 negative individuals [6,7]. The allelic variation in the APOE gene is shown to be a significant predictor of variation in the risk of coronary heart disease (CHD) and CHD death [2-4,8-10], but the results from an extensive prospective study showed no associations [11]. Both the MONICA Project [12] and the Scandinavian Simvastatin Survival Study [13] suggest an increased risk of CHD for individuals carrying the APOE epsilon4 allele. The APOE epsilon4 allele is also considered a strong risk factor for Alzheimer's disease [14-16].
###end p 13
###begin p 14
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 921 934 921 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;2</italic>
###xml 935 943 929 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;3</italic>
###xml 944 947 932 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e4 </italic>
###xml 40 46 <span type="species:ncbi:13443">coffee</span>
###xml 176 182 <span type="species:ncbi:13443">coffee</span>
###xml 311 317 <span type="species:ncbi:13443">coffee</span>
###xml 557 563 <span type="species:ncbi:13443">coffee</span>
###xml 587 593 <span type="species:ncbi:13443">coffee</span>
###xml 738 744 <span type="species:ncbi:13443">coffee</span>
The serum cholesterol-raising effect of coffee is due to the diterpenes kahweol and cafestol [17]. Earlier studies have shown a cholesterol-raising effect mainly of unfiltered coffee, because a major part of the diterpenes is retained by a paper filter [18-20]. A recent trial, however, indicates that filtered coffee has a more pronounced serum cholesterol-raising effect than previously anticipated [21]. This finding was further corroborated in a randomized intervention study, where we demonstrated a considerable cholesterol-raising effect of filtered coffee [22]. In the study two coffee abstention periods were associated with a significant decline in serum cholesterol of 0.22 and 0.36 mmol/L, respectively, while 600 mL filtered coffee a day during two different periods increased serum cholesterol by 0.25 and 0.15 mmol/L, respectively. Here, we test the hypothesis that these effects might be modulated by the APOE epsilon2/epsilon3/e4 polymorphism.
###end p 14
###begin title 15
Subjects and methods
###end title 15
###begin title 16
Trial design
###end title 16
###begin p 17
###xml 146 152 <span type="species:ncbi:13443">coffee</span>
###xml 264 270 <span type="species:ncbi:13443">coffee</span>
The study was organised as a prospective, controlled study with four consecutive trial periods. The first and third periods were 3 weeks of total coffee abstention. The second and fourth period consisted of 4 weeks with the subjects consuming 600 mL filter brewed coffee/day.
###end p 17
###begin p 18
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 171 177 <span type="species:ncbi:13443">coffee</span>
###xml 192 198 <span type="species:ncbi:13443">coffee</span>
###xml 304 310 <span type="species:ncbi:13443">coffee</span>
###xml 426 432 <span type="species:ncbi:13443">coffee</span>
The main outcome or effect variable was total serum cholesterol and the effect was assessed as the difference between the measurements at the beginning and the end of the coffee free periods (coffee abstention) and the difference between measurements at the beginning and at the end of the four weeks of coffee consumption (Figure 1). Trial duration of 3-4 weeks has previously been shown to be sufficient to get an effect of coffee on serum cholesterol [21,23].
###end p 18
###begin p 19
Study design
###end p 19
###begin title 20
Subjects and procedure
###end title 20
###begin p 21
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 272 284 <span type="species:ncbi:9606">participants</span>
###xml 380 386 <span type="species:ncbi:13443">coffee</span>
Participants were recruited by advertising in Gothenburg's major newspaper. Inclusion criteria were age-range 30-65 years, free from clinically recognized chronic diseases, such as cardiovascular diseases, cancer, renal disorders, liver disease and diabetes mellitus. The participants were required to be free from anti-epileptic or cholesterol lowering drugs, and had been using coffee on a regular basis for at least five years and were currently non-smokers (at least for the last six months).
###end p 21
###begin p 22
###xml 11 17 <span type="species:ncbi:13443">coffee</span>
###xml 39 51 <span type="species:ncbi:9606">participants</span>
###xml 104 110 <span type="species:ncbi:13443">coffee</span>
###xml 165 171 <span type="species:ncbi:13443">coffee</span>
###xml 272 278 <span type="species:ncbi:13443">coffee</span>
###xml 284 296 <span type="species:ncbi:9606">participants</span>
###xml 336 342 <span type="species:ncbi:13443">coffee</span>
During the coffee drinking periods the participants were instructed to drink about 600 mL filter brewed coffee/day (4 cups), according to standardised measures. The coffee was provided to guarantee that they were all exposed to the same brand and quality of filter brewed coffee. All participants also got the same kind of standardised coffee filter and measuring spoon.
###end p 22
###begin p 23
###xml 4 10 <span type="species:ncbi:13443">coffee</span>
###xml 42 46 <span type="species:ncbi:9319">Euro</span>
###xml 141 153 <span type="species:ncbi:9606">participants</span>
###xml 231 237 <span type="species:ncbi:13443">coffee</span>
The coffee filters used were of the brand Euro-Shopper, made by Indupa N.V., Zaventem, Belgium. Divergence from the 4 cups was reported. The participants were allowed to drink tea and other caffeine containing beverages during the coffee-free periods.
###end p 23
###begin title 24
Effect variables
###end title 24
###begin p 25
Non-fasting blood samples were drawn at inclusion and at three, seven, ten and fourteen weeks after start of the study. Prior to analysis, prepared serum was stored at -70degreesC.
###end p 25
###begin p 26
###xml 565 566 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
The blood samples were analysed for blood lipids (total cholesterol, HDL cholesterol, triglycerides, lipoprotein(a) (Lp(a)) and urate in serum. Serum cholesterol and triglycerides were determined by an enzymatic procedure on a Hitachi 917 analyzer. HDL cholesterol was determined enzymatically after precipitation of VLDL, LDL and chylomicrones by alpha-cyklodextrinsulphate and dextransulphate. Determination of Lp(a) was done by the method Tint Elize Lp(a) of Biopool International. Serum urate was analysed by Hitachi 917 autoanalyser. Body Mass Index (BMI; kg/m2) was recorded once during the study. Blood pressure was recorded by manual device and EKG and heart rate were recorded at all five visits.
###end p 26
###begin p 27
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
The dietary habits were assessed by dietary frequency questionnaires at the beginning of the study. A follow-up survey with special emphasis on changes in food habits during the four different periods was undertaken. The dietary questionnaire was based upon a Norwegian version, which has been used in a number of previous studies [24].
###end p 27
###begin title 28
Genotype Analysis
###end title 28
###begin p 29
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
APOE genotypes were determined by solid-phase minisequencing as previously described by Blennow et al [25].
###end p 29
###begin title 30
Statistical methods
###end title 30
###begin p 31
###xml 41 44 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#169;</sup>
All analyses were performed using the SAS(c)software version 8. Signed rank test was used to test differences in the groups. Wilcoxon rank sum test was used to test differences at baseline and differences between the groups. The mean was used as location measure and measures of variation were described in terms of standard deviation. P-values < 0.05 were considered statistically significant.
###end p 31
###begin title 32
Results
###end title 32
###begin p 33
###xml 15 22 <span type="species:ncbi:9606">persons</span>
###xml 128 135 <span type="species:ncbi:9606">persons</span>
###xml 197 209 <span type="species:ncbi:9606">participants</span>
###xml 215 221 <span type="species:ncbi:9606">person</span>
###xml 286 293 <span type="species:ncbi:9606">persons</span>
###xml 368 380 <span type="species:ncbi:9606">participants</span>
A total of 156 persons responded to the advertisement and of these 124 fulfilled the criteria and were able to take part. Three persons decided to withdraw during the study, leaving a total of 121 participants. One person was not able to take part during the first two periods and five persons were not able to take part in the last two periods, which resulted in 120 participants in the first trial period and 116 in the subsequent trial period.
###end p 33
###begin title 34
Genotype frequencies
###end title 34
###begin p 35
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 219 220 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 221 222 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 265 270 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 302 303 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
The APOE allele frequencies were 6.1% for the epsilon2 allele, 75.6% for the epsilon3 allele and 18.2% for the epsilon4 allele. This distribution agrees well with those reported in other populations in northern Europe [2,3]. Genotype and allele frequencies for the APOE polymorphism are given in Table 1.
###end p 35
###begin p 36
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
APOE genotype and allele frequency, n = 121
###end p 36
###begin title 37
###xml 59 65 <span type="species:ncbi:13443">coffee</span>
Serum cholesterol concentrations according to genotype and coffee exposure
###end title 37
###begin p 38
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 48 49 48 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 443 451 431 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;2</italic>
###xml 561 562 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 898 899 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 971 972 947 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 88 94 <span type="species:ncbi:13443">coffee</span>
###xml 317 323 <span type="species:ncbi:13443">coffee</span>
###xml 757 763 <span type="species:ncbi:13443">coffee</span>
###xml 859 865 <span type="species:ncbi:13443">coffee</span>
Individual APOE genotypes (six subgroups, Table 1) did not influence baseline values or coffee-induced changes in serum cholesterol, serum HDL cholesterol, serum triglycerides or serum Lp(a), possibly due to a small sample size (data not shown). epsilon4-positive individuals had similar serum cholesterol levels and coffee-induced changes in cholesterol concentration as epsilon4-negative individuals (data not shown). However, when grouping epsilon2-positive individuals it was revealed that these displayed significantly lower cholesterol at baseline (Table 2). There was a significant difference in cholesterol decrease between week 0 and 3 for both groups. There was no difference between the two groups regarding the cholesterol decrease in the first coffee abstention period but there was a significant difference in cholesterol decrease in the second coffee abstention period, where epsilon2-negative individuals displayed a larger decrease in cholesterol (Table 2).
###end p 38
###begin p 39
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 148 149 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 172 177 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 184 185 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 85 91 <span type="species:ncbi:13443">coffee</span>
Serum cholesterol concentration (mmol/L) at baseline and after two 3-week periods of coffee abstention (week 0 - 3 and week 7 - 10) for APOE epsilon2-positive (n = 13) and APOE epsilon2-negative (n = 108) individuals
###end p 39
###begin p 40
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 6 18 <span type="species:ncbi:9606">participants</span>
###xml 53 65 <span type="species:ncbi:9606">participants</span>
a 107 participants in the first trial period and 103 participants in the second trial period
###end p 40
###begin p 41
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 45 46 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 60 65 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 72 73 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
b Significant difference between APOE epsilon2-positive and APOE epsilon2-negative at baseline, Wilcoxon rank sum test
###end p 41
###begin p 42
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 48 49 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 63 68 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 75 76 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
c No significant difference between APOE epsilon2-positive and APOE epsilon2-negative in differences between week 0-3 or week 7-10, Wilcoxon rank sum test
###end p 42
###begin p 43
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 62 63 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 122 127 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 134 135 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
d Significant difference between week 0-3 for the APOE epsilon2-positive group and between week 0-3 and week 7-10 for the APOE epsilon2-negative group, Signed rank test
###end p 43
###begin p 44
###xml 80 81 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 162 163 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 186 187 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 235 236 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 261 262 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 400 401 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 0 6 <span type="species:ncbi:13443">Coffee</span>
###xml 355 361 <span type="species:ncbi:13443">coffee</span>
Coffee consumption resulted in a significant cholesterol increase in the epsilon2-negative group in both trial periods (w 3-7 and w 10-14), but not in the epsilon2-positive group (Table 3). There were no differences between the epsilon2-positive and the epsilon2-negative group according to baseline characteristics as sex, age, body mass index (BMI) and coffee consumption prior to the study (Table 4).
###end p 44
###begin p 45
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 134 135 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 158 163 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 170 171 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 69 75 <span type="species:ncbi:13443">coffee</span>
Serum cholesterol concentration (mmol/L) after two 4-week periods of coffee consumption (week 3 - 7 and week 10 - 14) for APOE epsilon2-positive (n = 13) and APOE epsilon2-negative (n = 108) individuals
###end p 45
###begin p 46
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 6 18 <span type="species:ncbi:9606">participants</span>
###xml 53 65 <span type="species:ncbi:9606">participants</span>
a 107 participants in the first trial period and 103 participants in the second trial period
###end p 46
###begin p 47
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b No significant difference between 2-positive and 2-negative in differences between week 3-7 or week 10-14, Wilcoxon rank sum test
###end p 47
###begin p 48
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 76 77 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
c Significant difference between week 0-3 and week 7-10 for the APOE epsilon2-negative group, Signed rank test
###end p 48
###begin p 49
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 41 42 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 65 70 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 77 78 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
Baseline characteristics for APOE epsilon2-positive (n = 13) and APOE epsilon2-negative (n = 108) individuals
###end p 49
###begin p 50
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 48 49 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 63 68 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 75 76 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
a No significant difference between APOE epsilon2-positive and APOE epsilon2-negative at baseline, Chi square test
###end p 50
###begin p 51
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 48 49 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 63 68 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 75 76 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
b No significant difference between APOE epsilon2-positive and APOE epsilon2-negative at baseline, Wilcoxon rank sum test
###end p 51
###begin title 52
Dietary monitoring and compliance
###end title 52
###begin p 53
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 99 105 <span type="species:ncbi:13443">Coffee</span>
###xml 156 163 <span type="species:ncbi:9606">persons</span>
###xml 181 187 <span type="species:ncbi:13443">coffee</span>
###xml 243 250 <span type="species:ncbi:9606">persons</span>
###xml 260 266 <span type="species:ncbi:13443">coffee</span>
###xml 293 299 <span type="species:ncbi:13443">coffee</span>
The dietary survey did not reveal any important changes during the four intervention periods [22]. Coffee consumption or non-compliance was reported by six persons during the first coffee abstention period (mean 1.8 cups/period), whereas four persons reported coffee consumption in the second coffee abstention period (mean 0.7 cups/period).
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 298 312 298 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE e2/e3/e4 </italic>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 429 434 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 644 649 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 708 714 <span type="species:ncbi:13443">coffee</span>
Subjects with different APOE genotypes differ in the absorption efficiency of cholesterol from the intestine, in the synthesis rates of cholesterol and bile acids, and in the production of LDL apoprotein B [3,26]. This suggests that the response of serum cholesterol to diet may be affected by the APOE e2/e3/e4 polymorphism [27,28]. One previous study examined the effect of purified cafestol on serum lipids in relation to the APOE polymorphism [26] and found that responses of LDL-cholesterol to cafestol were slightly smaller among carriers of the APOE epsilon4 allele. Here, we investigate for the first time the possible influence of the APOE polymorphism on the cholesterol-raising effect of filtered coffee.
###end p 55
###begin p 56
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 380 388 356 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;2</italic>
###xml 613 626 583 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;2</italic>
###xml 627 635 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;3</italic>
###xml 636 645 594 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;4 </italic>
###xml 152 158 <span type="species:ncbi:13443">coffee</span>
###xml 478 484 <span type="species:ncbi:13443">coffee</span>
###xml 724 730 <span type="species:ncbi:13443">coffee</span>
###xml 873 879 <span type="species:ncbi:13443">coffee</span>
APOE epsilon4-positive individuals did not differ significantly from epsilon4-negative individuals with regard to baseline cholesterol concentration or coffee-induced changes in cholesterol concentration. However, we confirm that epsilon2-positive individuals display significantly lower cholesterol levels at baseline than epsilon2-negative individuals. A tendency was seen that epsilon2-positive individuals might be partly protected from the cholesterol increasing effect of coffee consumption. This was, however, only seen in the first trial period and will require further investigations. In conclusion, the APOE epsilon2/epsilon3/epsilon4 polymorphism is not a strong modulator of the cholesterol-increasing effect of coffee. Other genes should be discussed and further investigation is needed to see if there is a genetic factor in the cholesterol-raising effect of coffee.
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
This work was supported by grants from the Swedish Medical Research Council (project #12103), the Sahlgrenska University Hospital and the Swedish Council for Working Life and Social Research.
###end p 58
###begin article-title 59
Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study
###end article-title 59
###begin article-title 60
Apolipoprotein E polymorphism and atherosclerosis
###end article-title 60
###begin article-title 61
Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review
###end article-title 61
###begin article-title 62
APOLIPOPROTEIN E: Far More Than a Lipid Transport Protein
###end article-title 62
###begin article-title 63
Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease
###end article-title 63
###begin article-title 64
###xml 84 92 <span type="species:ncbi:9606">Children</span>
Apolipoprotein E Phenotype Regulates Cholesterol Absorption in Healthy 13-Month-Old Children-The STRIP Study
###end article-title 64
###begin article-title 65
###xml 86 93 <span type="species:ncbi:9606">infants</span>
Apolipoprotein E4 phenotype increases non-fasting serum triglyceride concentration in infants - the STRIP study
###end article-title 65
###begin article-title 66
###xml 144 147 <span type="species:ncbi:9606">men</span>
Genotypes with the apolipoprotein epsilon4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men
###end article-title 66
###begin article-title 67
###xml 111 114 <span type="species:ncbi:9606">men</span>
Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men. An autopsy study
###end article-title 67
###begin article-title 68
Polymorphisms in the Apolipoprotein E gene regulatory region in relation to coronary heart disease and their effect on plasma Apolipoprotein E
###end article-title 68
###begin article-title 69
###xml 124 127 <span type="species:ncbi:9606">men</span>
A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men
###end article-title 69
###begin article-title 70
###xml 85 88 <span type="species:ncbi:9606">men</span>
An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E
###end article-title 70
###begin article-title 71
###xml 19 19 19 19 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1476-511X-3-26-i1.gif"/>
The apolipoprotein  allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. A substudy of the Scandinavian Simvastatin Survival Study
###end article-title 71
###begin article-title 72
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
###end article-title 72
###begin article-title 73
Apolipoprotein E polymorphism and Alzheimer's disease
###end article-title 73
###begin article-title 74
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease
###end article-title 74
###begin article-title 75
###xml 36 42 <span type="species:ncbi:13443">coffee</span>
The cholesterol-raising factor from coffee beans
###end article-title 75
###begin article-title 76
###xml 0 6 <span type="species:ncbi:13443">Coffee</span>
Coffee and cardiovascular risk; an epidemiological study
###end article-title 76
###begin article-title 77
###xml 43 49 <span type="species:ncbi:13443">coffee</span>
The hypercholesterolaemic factor of boiled coffee is retained by a paper filter
###end article-title 77
###begin article-title 78
###xml 39 45 <span type="species:ncbi:13443">coffee</span>
Cholesterol-raising factor from boiled coffee does not pass a paper filter
###end article-title 78
###begin article-title 79
###xml 25 31 <span type="species:ncbi:13443">coffee</span>
Abstention from filtered coffee reduces the levels of homocysteine and cholesterol - a randomized, controlled trial
###end article-title 79
###begin article-title 80
###xml 9 15 <span type="species:ncbi:13443">coffee</span>
Filtered coffee raises serum cholesterol: results from a controlled study
###end article-title 80
###begin article-title 81
###xml 11 17 <span type="species:ncbi:13443">coffee</span>
Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomized trial
###end article-title 81
###begin article-title 82
###xml 85 90 <span type="species:ncbi:9606">women</span>
Accuracy of a quantitative food frequency questionnaire applied in elderly Norwegian women
###end article-title 82
###begin article-title 83
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
###end article-title 83
###begin article-title 84
Apoprotein E genotype and the response of serum cholesterol to dietary fat, cholesterol and cafestol
###end article-title 84
###begin article-title 85
Genetic variation and the lipid response to dietary intervention: a systematic review
###end article-title 85
###begin article-title 86
Gene-diet interaction and plasma lipid responses to dietary intervention
###end article-title 86

